Natera (NTRA) – Business Wire
-
Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer
-
New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease
-
Natera to Present New Data at the 2024 SGO Annual Meeting on Women’s Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers
-
Natera Announces Commercial Coverage for Prospera™ Kidney and Prospera Heart™ from a Top BCBS Plan
-
Natera to Participate in March Investor Conferences
-
Natera Reports Fourth Quarter and Full Year 2023 Financial Results
-
Natera Announces Next Phase of CareDx Patent Infringement Litigation Seeking Royalty For All Ongoing And Future AlloSure Tests
-
Medicare Extends Coverage of Natera’s Signatera™ MRD Test to Ovarian Cancer and Neoadjuvant Breast Cancer
-
Natera Announces Fourth Quarter and Fiscal 2023 Earnings Conference Call
-
New Study Validates Signatera™ in Endometrial Cancer
-
New Publication Demonstrates Signatera’s Ability to Risk Stratify and Detect Recurrence Early in Resected Stage I-II Lung Cancer
-
Jury Rules in Favor of Natera in Patent Infringement Lawsuit Against CareDx; Awards $96.3 Million in Damages to Natera in Lost Profits and Past Royalties
-
CareDx Issues Statement in Patent Infringement Case
-
Nature Medicine Publishes Two Studies Highlighting Signatera’s Clinical Utility in Patients with Gastrointestinal Malignancies
-
Natera Acquires Reproductive Health Assets from Invitae
-
Natera to Present New Data from the CIRCULATE-Japan and BESPOKE CRC Studies at ASCO GI 2024 Supporting Signatera’s Clinical Utility in CRC
-
Natera Provides Update on Ravgen Trial
-
Natera Announces Preliminary Fourth Quarter and Full Year 2023 Revenues
-
Natera to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
-
Natera Wins Preliminary Injunction in Patent Infringement Lawsuit Against NeoGenomics’ RaDaR Test
-
Natera Announces New Study Highlighting the Benefits of Signatera’s Unique Method of Quantifying ctDNA
-
Delaware Court Denies CareDx’s Motion for Summary Judgment on Two Natera Patents
-
Natera Presents New Signatera™ MRD Data Across Breast Cancer Treatment Settings at SABCS 2023
-
Natera Announces Real-World Data Collaboration with Merck
-
Natera Reports Third Quarter 2023 Financial Results
-
Natera Announces Randomized, Phase III TREAT ctDNA Trial in Early-Stage Breast Cancer
-
Natera to Participate in November Investor Conferences
-
Natera’s Landmark RenaCARE Study Demonstrates Significant Diagnostic and Clinical Utility of Renasight™ in Chronic Kidney Disease
-
Updated Data from CIRCULATE-Japan Presented at ESMO 2023 Reinforces Signatera’s Prognostic and Predictive Value in Analysis of 2,500+ Colorectal Cancer Patients
-
Natera to Report its Third Quarter 2023 Results on November 8
-
Natera Recognized on U.S. News & World Report’s 2024 Best Companies to Work for in Healthcare Ranking
-
Natera to Present New Signatera™ MRD Data at ESMO 2023, Featuring Large, Updated Analysis from CIRCULATE-Japan Study
-
New MRD Publication in Unresectable Stage I-III Lung Cancer Demonstrates Signatera’s Ability to Risk Stratify and Detect Progression Early
-
Supreme Court Denies CareDx Request for Appeal in Patent Case with Natera
-
Natera Submits First PMA Module to the FDA for Signatera™
-
Natera Announces Senior Leadership Appointments
-
Natera Announces Expanded I-SPY 2 Collaboration to Evaluate Signatera™ for Breast Cancer Patients in the Neoadjuvant Setting
-
Natera Announces Pricing of $250 Million Follow-On Offering
-
Natera Launches Proposed Follow-On Offering
-
Natera to Participate in Upcoming Investor Conferences
-
Natera’s Prospera™ Lung Transplant Assessment Test Granted Medicare Coverage
-
CareDx Announces District Court Judge Bars Natera from Falsely Advertising and Overstating the Scientific Performance of its Prospera Transplant Test
-
Natera Reports Second Quarter 2023 Financial Results
-
Natera to Participate in Canaccord Genuity 43rd Annual Growth Conference
-
Natera Files Patent Infringement Suit Against NeoGenomics
-
Natera Announces Completion of Enrollment to the Randomized, Phase III ALTAIR Trial of Signatera™ in Colorectal Cancer
-
Natera to Report its Second Quarter 2023 Results on August 3rd
-
CareDx Applauds District Court Decision to Uphold Jury Verdict that Natera Falsely Advertised its Prospera Transplant Test
-
Court Issues Favorable Ruling for Natera in False Advertising Trial Against CareDx; Eliminates all Damages
-
Natera to Participate in Goldman Sachs 44th Annual Global Healthcare Conference
Back to NTRA Stock Lookup